Physician profile
Igor Smelyansky
NPI 1295818409
$11,860.89
in general payments reported to CMS, 2019-2025
44 companies · $719 in 2025
The $719 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,033 · 2020: $483 · 2021: $2,901 · 2022: $2,953 · 2023: $1,853 · 2024: $1,920 · 2025: $719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,076 · Travel and Lodging: $367 · Education: $49.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,076.03 |
| Travel and Lodging | $366.96 |
| Education | $49.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,764.17 | 2021-2024 | Intellis Adaptivestim |
| Collegium Pharmaceutical, INC. | $1,283.13 | 2019-2025 | Xtampza, Belbuca |
| Abbvie INC. | $1,249.62 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,100.59 | 2019-2025 | Relistor |
| Pfizer INC. | $683.95 | 2019-2025 | |
| Curonix LLC | $521.89 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Scilex Pharmaceuticals INC. | $485.13 | 2019-2025 | Ztlido |
| Biohaven Pharmaceutical Holding Company LTD. | $398.92 | 2022 | |
| Nevro Corp. | $372.81 | 2019-2023 | Senza |
| Impel Pharmaceuticals INC. | $341.89 | 2023 | Trudhesa |
| Lilly USA, LLC | $281.37 | 2021-2023 | Emgality, Reyvow |
| Boston Scientific Corporation | $274.73 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $267.14 | 2019-2025 | Eterna, Proclaim |
| Arbor Pharmaceuticals, INC. | $215.59 | 2019-2022 | |
| Amgen INC. | $215.36 | 2019-2023 | Aimovig |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Smelyansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.